Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03173066 · ClinicalTrials.gov registry record · Phase 1
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03173066 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 1 participants.
The verdict
NCT03173066, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This proposal is based on findings from our previous work involving ferumoxytol-enhanced cardiac magnetic resonance angiography. The resolution of the pulmonary vasculature based on our previous imaging protocol was exceptional (PMID: 26786296). In the Partners Healthcare System between January 1, 2014 and January 1, 2015 there were 541 patients evaluated in Partners Healthcare-affiliated hospitals with a diagnosis of pulmonary embolism and acute or chronic kidney disease at the same visit between 01/01/2014 and 01/01/2015. Ventilation perfusion scanning was performed in 201 patients during this same time interval. Up to 63% of these patients in one year did not receive the diagnostic test of choice.
Interventions
- DRUG Ferumoxytol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03173066
The ClinicalTrials.gov registry entry for NCT03173066 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ferumoxytol is the first listed.
NCT03173066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03173066 about?
NCT03173066 is a clinical study titled "Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography". This proposal is based on findings from our previous work involving ferumoxytol-enhanced cardiac magnetic resonance angiography. The resolution of the pulmonary vasculature based on our previous imaging protocol was exceptional (PMID: 26786296). In the Partners Healthcare System between January 1, 2...
What is the current status of trial NCT03173066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2018-09-21. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT03173066?
The interventions under investigation include: Ferumoxytol (DRUG).
Who is sponsoring clinical trial NCT03173066?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.